📣 VC round data is live. Check it out!

Insulet Valuation Multiples

Discover revenue and EBITDA valuation multiples for Insulet and similar public comparables like Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical and more.

Insulet Overview

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.


Founded

2000

HQ

United States

Employees

5.4K

Financials (LTM)

Revenue: $3B
EBITDA: $693M

EV

$12B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Insulet Financials

Insulet reported last 12-month revenue of $3B and EBITDA of $693M.

In the same LTM period, Insulet generated $2B in gross profit, $693M in EBITDA, and $385M in net income.

Revenue (LTM)


Insulet P&L

In the most recent fiscal year, Insulet reported revenue of $3B and EBITDA of $640M.

Insulet is profitable as of last fiscal year, with gross margin of 72%, EBITDA margin of 24%, and net margin of 13%.

See analyst estimates for Insulet
LTMLast FY202320242025202620272028
Revenue$3B$3B$2B$2B$3B
Gross Profit$2B$2B$1B$1B$2B
Gross Margin72%72%68%70%72%
EBITDA$693M$640M$324M$424M$489M
EBITDA Margin24%24%19%20%18%
EBIT Margin18%18%13%15%17%
Net Profit$385M$354M$206M$418M$247M
Net Margin13%13%12%20%9%
Net Debt—$233M———

Financial data powered by Morningstar, Inc.

Insulet Stock Performance

Insulet has current market cap of $12B, and enterprise value of $12B.

Market Cap Evolution


Insulet's stock price is $175.04.

Insulet share price increased by 1.7% in the last 30 days, and decreased by 46.1% in the last year.

Insulet has an EPS (earnings per share) of $5.12.

See more trading valuation data for Insulet
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$12B$12B-0.0%1.7%-29.0%-46.1%$5.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Insulet Valuation Multiples

Insulet trades at 4.2x EV/Revenue multiple, and 17.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Insulet

EV / Revenue (LTM)


Insulet Financial Valuation Multiples

As of May 4, 2026, Insulet has market cap of $12B and EV of $12B.

Insulet has a P/E ratio of 31.5x.

LTMLast FY202320242025202620272028
EV/Revenue4.2x4.6x7.3x6.0x4.6x
EV/EBITDA17.8x19.3x38.2x29.2x25.3x
EV/EBIT23.6x26.0x56.2x40.0x26.1x
EV/Gross Profit5.9x6.4x10.7x8.5x6.4x
P/E31.5x34.2x58.8x29.0x49.1x
EV/FCF31.5x33.8xn/m41.7x35.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Insulet Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Insulet Margins & Growth Rates

Insulet grew revenue by 22% and EBITDA by 25% in the last fiscal year.

In the most recent fiscal year, Insulet reported gross margin of 72%, EBITDA margin of 24%, and net margin of 13%.

See estimated margins and future growth rates for Insulet

Insulet Margins

Last FY202420252026202720282029
Gross Margin72%70%72%72%
EBITDA Margin24%20%18%24%
EBIT Margin18%15%17%19%
Net Margin13%20%9%13%
FCF Margin13%14%13%13%

Insulet Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%22%31%22%
Gross Profit Growth23%25%34%23%
EBITDA Growth25%31%15%63%
EBIT Growth29%40%53%29%
Net Profit Growth26%103%(41%)80%
FCF Growth22%712%18%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Insulet Operational KPIs

Insulet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Insulet's Rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Insulet's Rule of X is 80% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Insulet
LTMLast FY202320242025202620272028
Rule of 4045%46%———
Bessemer Rule of X77%80%———
Revenue per Employee—$0.5M———
Opex per Employee—$0.3M———
S&M Expenses to Revenue4%4%——4%
G&A Expenses to Revenue11%11%——11%
R&D Expenses to Revenue11%11%12%11%11%
Opex to Revenue—54%55%55%54%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Insulet Competitors

Insulet competitors include Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Solventum, Penumbra, Align Technology, Sonova and Olympus.

Most Insulet public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cooper Companies3.6x3.5x11.3x10.9x
Medpace4.5x4.4x20.2x19.8x
Fresenius Medical Care1.0x1.0x5.4x5.4x
Globus Medical4.1x3.9x14.7x12.4x
Fisher & Paykel16.5x9.1x32.2x26.7x
Solventum1.9x1.9x6.2x7.1x
Penumbra8.9x8.5x55.7x44.2x
Align Technology2.9x2.9x10.9x10.6x

This data is available for Pro users. Sign up to see all Insulet competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Insulet

When was Insulet founded?Insulet was founded in 2000.
Where is Insulet headquartered?Insulet is headquartered in United States.
How many employees does Insulet have?As of today, Insulet has over 5K employees.
Who is the CEO of Insulet?Insulet's CEO is Ashley A. McEvoy.
Is Insulet publicly listed?Yes, Insulet is a public company listed on Nasdaq.
What is the stock symbol of Insulet?Insulet trades under PODD ticker.
When did Insulet go public?Insulet went public in 2007.
Who are competitors of Insulet?Insulet main competitors include Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Solventum, Penumbra, Align Technology, Sonova, Olympus.
What is the current market cap of Insulet?Insulet's current market cap is $12B.
What is the current revenue of Insulet?Insulet's last 12 months revenue is $3B.
What is the current revenue growth of Insulet?Insulet revenue growth (NTM/LTM) is 21%.
What is the current EV/Revenue multiple of Insulet?Current revenue multiple of Insulet is 4.2x.
Is Insulet profitable?Yes, Insulet is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Insulet?Insulet's last 12 months EBITDA is $693M.
What is Insulet's EBITDA margin?Insulet's last 12 months EBITDA margin is 24%.
What is the current EV/EBITDA multiple of Insulet?Current EBITDA multiple of Insulet is 17.8x.
What is the current FCF of Insulet?Insulet's last 12 months FCF is $393M.
What is Insulet's FCF margin?Insulet's last 12 months FCF margin is 13%.
What is the current EV/FCF multiple of Insulet?Current FCF multiple of Insulet is 31.5x.
How many companies Insulet has acquired to date?Insulet hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Insulet has invested to date?Insulet hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Insulet

Lists including Insulet

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial